These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33540768)

  • 1. Functional Assessment of 12 Rare Allelic
    Kumondai M; Ito A; Gutiérrez Rico EM; Hishinuma E; Ueda A; Saito S; Nakayoshi T; Oda A; Tadaka S; Kinoshita K; Maekawa M; Mano N; Hirasawa N; Hiratsuka M
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33540768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells.
    Du H; Wei Z; Yan Y; Xiong Y; Zhang X; Shen L; Ruan Y; Wu X; Xu Q; He L; Qin S
    Front Pharmacol; 2016; 7():98. PubMed ID: 27199745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of 32 CYP2C9 allelic variants.
    Niinuma Y; Saito T; Takahashi M; Tsukada C; Ito M; Hirasawa N; Hiratsuka M
    Pharmacogenomics J; 2014 Apr; 14(2):107-14. PubMed ID: 23752738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
    Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
    Chang TK; Yu L; Goldstein JA; Waxman DJ
    Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Characterization of 29 Cytochrome P450 4F2 Variants Identified in a Population of 8380 Japanese Subjects and Assessment of Arachidonic Acid
    Sato Y; Hishinuma E; Yamazaki S; Ueda A; Kumondai M; Saito S; Tadaka S; Kinoshita K; Nakayoshi T; Oda A; Maekawa M; Mano N; Hirasawa N; Hiratsuka M
    Drug Metab Dispos; 2023 Dec; 51(12):1561-1568. PubMed ID: 37775333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Enzymatic Activity Evaluation of a Novel
    Zhou XY; Lu XR; Li YH; Ma YQ; Zhao SW; Wang F; Xu RA; Hu GX; Cai JP
    Front Pharmacol; 2021; 12():619339. PubMed ID: 33643050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation.
    Watanabe T; Saito T; Rico EMG; Hishinuma E; Kumondai M; Maekawa M; Oda A; Saigusa D; Saito S; Yasuda J; Nagasaki M; Minegishi N; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
    Biochem Pharmacol; 2018 Oct; 156():420-430. PubMed ID: 30201214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.
    Schwarz UI
    Eur J Clin Invest; 2003 Nov; 33 Suppl 2():23-30. PubMed ID: 14641553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population.
    Dai DP; Wang YH; Wang SH; Geng PW; Hu LM; Hu GX; Cai JP
    Acta Pharmacol Sin; 2013 Nov; 34(11):1449-56. PubMed ID: 24077631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B; Wang J; Huang SQ; Su HH; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
    He SM; Zhou ZW; Li XT; Zhou SF
    Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro.
    Wang L; Bao SH; Pan PP; Xia MM; Chen MC; Liang BQ; Dai DP; Cai JP; Hu GX
    Drug Dev Ind Pharm; 2015; 41(8):1363-7. PubMed ID: 25144335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People.
    McDonald MG; Henderson LM; Ray S; Yeung CK; Johnson AL; Kowalski JP; Hanenberg H; Wiek C; Thummel KE; Rettie AE
    J Pharmacol Exp Ther; 2020 Aug; 374(2):233-240. PubMed ID: 32423989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.